Cocrystal Pharma Reports 2025 Financial Results and Significant Advances in Antiviral Pipeline

Key Highlights

• Norovirus Program Milestone: Phase 1b human challenge study for CDI-988, the first oral antiviral candidate for norovirus, is underway at Emory University School of Medicine. This marks a potentially transformative step with no current approved treatments or vaccines for norovirus, a virus that causes a global economic burden of \$60 billion annually.
• Pipeline Expansion: CDI-988 also targets a highly conserved region of the 3CL protease found in all known norovirus strains, and holds promise as a broad-spectrum antiviral effective against coronaviruses.
• Influenza Program Progress: CC-42344, the company’s novel PB2 inhibitor, is being advanced both as an oral and inhaled therapeutic, with recent clinical and preclinical milestones in pandemic/seasonal influenza and avian influenza strains, including the 2024 Texas H5N1 strain.
• Financial Performance: Net loss narrowed to \$8.8 million for 2025 (vs. \$17.5 million for 2024). As of December 31, 2025, Cocrystal reported \$7.7 million in unrestricted cash, 11.3 million common shares outstanding, and working capital of \$5.9 million.

Detailed Pipeline and Program Updates

Norovirus: Unmet Clinical Need and CDI-988 Progress

Norovirus remains a highly challenging and underserved market with no effective treatments or vaccines. Annually, there are an estimated 685 million global cases, leading to \$60 billion in worldwide economic impact. In the U.S. alone, norovirus is responsible for 21 million infections, over 100,000 hospitalizations, and nearly 900 deaths each year.

Cocrystal’s lead oral protease inhibitor, CDI-988, is the first clinical candidate targeting norovirus using a pan-3CL protease inhibitor strategy. Notably:

• CDI-988 showed superior broad-spectrum antiviral activity against the prevalent GII.17 strain in the U.S. and Europe (2024–2025).
• Favorable Phase 1 safety/tolerability data was presented in August 2025, including up to 1200 mg dose cohorts.
• Received FDA clearance (Study May Proceed Letter) in September 2025 for a U.S. Phase 1b challenge study (prevention and treatment evaluation).
• First cohort enrolled in March 2026, with subsequent cohorts to receive CDI-988 or placebo under controlled challenge conditions.

The ongoing challenge study at Emory University is a randomized, double-blind, placebo-controlled trial enrolling up to 40 subjects. Primary endpoint: reduction of clinical symptoms; secondary endpoints: viral shedding, disease severity, safety, and pharmacokinetics.

Potential Share Price Impact: If CDI-988 demonstrates efficacy and safety in the ongoing Phase 1b trial, this could create substantial value for Cocrystal, given the lack of approved norovirus treatments and the large market opportunity.

Influenza Pipeline: CC-42344 and New Programs

• CC-42344 (Oral, Influenza A):
  • Favorable Phase 1 safety/tolerability results (December 2022).
  • Phase 2a human challenge study initiated in the UK (December 2023), assessing safety, viral, and clinical outcomes.
  • Active against highly pathogenic Texas H5N1 avian influenza (May 2025).
  • Phase 2a study completed (November 2025) with no serious adverse events or drug-related discontinuations, but efficacy analyses were inconclusive due to trial conduct issues. A new Phase 2a study is planned.
• CC-42344 (Inhaled): Preclinical data show superior lung pharmacology; dry powder formulation and toxicology studies completed.
• Influenza A/B Polymerase Program: Awarded \$500,000 NIH SBIR Phase I grant (October 2025) to develop a novel, broad-spectrum candidate targeting the influenza A/B polymerase complex.

Potential Share Price Impact: Continued progress and any positive results from ongoing or planned Phase 2a studies in pandemic/seasonal influenza could significantly enhance the company’s prospects, especially given growing concerns over viral resistance and emerging flu strains.

COVID-19 and Other Coronavirus Developments

CDI-988 also displayed potent in vitro pan-viral activity against SARS-CoV-2, common human coronaviruses, rhinoviruses, and respiratory enteroviruses. With the COVID-19 therapeutics market projected to exceed \$16 billion by 2031, further development of CDI-988 as prophylaxis/treatment for coronaviruses remains ongoing.

• August 2025: Favorable Phase 1 safety and tolerability data for CDI-988 presented.
• Plans to advance CDI-988 for both norovirus and coronavirus indications.

Potential Share Price Impact: Positive clinical data or regulatory progress in the coronavirus indication could open large new markets for CDI-988, adding significant upside potential.

Financial Overview

• 2025 R&D Expenses: \$5.1 million (down from \$12.5 million in 2024, reflecting lower costs from winding down the Phase 2a influenza study and reduced employee expenses).
• 2025 G&A Expenses: \$4.0 million (down from \$5.3 million in 2024).
• Net Loss 2025: \$8.8 million or \$0.78 per share (improved from \$17.5 million or \$1.72 per share in 2024).
• Unrestricted Cash (Dec 31, 2025): \$7.7 million (vs \$9.9 million in 2024).
• Net Cash Used in Operations 2025: \$8.2 million (vs \$16.5 million in 2024).
• Working Capital (Dec 31, 2025): \$5.9 million.
• Shares Outstanding (Dec 31, 2025): 11.3 million.

The significant reduction in operating expenses and narrowing of net losses reflects disciplined cost management, but cash reserves are lower, indicating the need for careful monitoring of funding needs as pipeline programs advance.

Strategic Outlook and Shareholder Considerations

• CDI-988 is a potential first-in-class oral antiviral for norovirus and coronaviruses, targeting large, underserved markets with significant economic and healthcare impacts.
• CC-42344 provides exposure to the large influenza market, with progress in both oral and inhaled formulations.
• The company’s structure-based drug discovery platform offers competitive advantages in speed, resistance-profiles, and broad-spectrum activity.
• Any positive trial results, regulatory designations, or partnership announcements could have an outsized effect on share price, given the high unmet need and rarity of direct competitors in the norovirus space.
• Investors should monitor cash runway, upcoming clinical data readouts, and further regulatory milestones for both CDI-988 and CC-42344.
• Potential risks include: trial delays, inability to recruit for studies, regulatory changes, competition from other antivirals, and ongoing macroeconomic/geopolitical uncertainties.

Contact and Further Information

Investor Relations:
Alliance Advisors IR
Jody Cain, 310-691-7100, [email protected]
www.cocrystalpharma.com

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. Investors should review the company’s filings with the SEC, including risk factors in the latest Annual Report, and consult their financial advisor before making investment decisions. The author accepts no responsibility for any actions taken based on this report.

View Cocrystal Pharma, Inc. Historical chart here